332 Table 3 | The discriminative ability of serological biomarkers with regard to disease behavior subtypes in patients with Crohn’s disease. Table 3. The discriminative ability of serological biomarkers with regard to disease behavior subtypes in patients with Crohn’s disease. Unadjusted Adjusted (full model)† Adjusted (residual marker value)‡ Non-penetrating, non-stricturing CD (Montreal B1) vs. stricturing CD (Montreal B2) Biomarker AUC (95% CI) Nominal P-value AUC (95% CI) P-value AUC (95% CI) P-value C1M 0.69 (0.56-0.83) 0.009 0.91 (0.84-0.98) < 0.001 0.78 (0.67-0.89) < 0.001 C3M 0.66 (0.53-0.80) 0.028 0.92 (0.84-0.99) < 0.001 0.91 (0.83-0.98) < 0.001 PRO-C3 0.52 (0.38-0.67) 0.760 C3M/PRO-C3 0.61 (0.47-0.75) 0.126 C4M 0.68 (0.55-0.82) 0.013 0.92 (0.85-0.99) < 0.001 0.87 (0.79-0.96) < 0.001 PRO-C4 0.57 (0.42-0.71) 0.359 PRO-C4/C4M 0.71 (0.57-0.84) 0.005 0.92 (0.85-0.99) < 0.001 0.90 (0.82-0.98) < 0.001 C4G 0.50 (0.36-0.65) 0.962 C6Ma3 0.59 (0.44-0.73) 0.234 Unadjusted Adjusted (full model)†† Adjusted (residual marker value)‡ Non-penetrating, non-stricturing CD (Montreal B1) vs. penetrating CD (Montreal B3) Biomarker AUC (95% CI) Nominal P-value AUC (95% CI) P-value AUC (95% CI) P-value C1M 0.51 (0.38-0.64) 0.877 C3M 0.52 (0.39-0.65) 0.775 PRO-C3 0.58 (0.45-0.71) 0.232 C3M/PRO-C3 0.58 (0.45-0.71) 0.236 C4M 0.52 (0.39-0.65) 0.791
RkJQdWJsaXNoZXIy MjY0ODMw